Viridian Therapeutics
VRDN on Nasdaq. Viridian Therapeutics makes medicines for people with autoimmune and rare diseases. Market value $3.5bn.
Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to December 2025.
We can't read total debt from the filing, so debt is left out.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
Nothing stands out yet.
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $-10.09 of spare cash in the past 12 months. A savings account pays about $4.
The filings do not give us enough to work this out.
Each dollar kept in the business earns -43 cents a year. Above 10 is good.
Quality score: 30 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.
$29.96 a share, 127% above its 1-year low
Over the past year the price has ranged from $13.18 to $34.29.
Pays no dividend
Prices from Friday’s close (20 November).
Five years of cash, in billions
| Revenue | |||||
| Revenue | $3m | $2m | $314,000 | $302,000 | $71m |
| Operating margin | |||||
| Operating margin | -2690.8% | -7579.2% | -81035.0% | -99018.2% | -512.9% |
| Debt to equity | |||||
| Debt to equity | 0.00 | 0.01 | 0.05 | 0.03 | n/a |
| Shares outstanding | |||||
| Shares outstanding | 0.04bn | 0.05bn | 0.08bn | 0.10bn | 0.11bn |
Health checks
- Free cash flow positive0 of 5 years
- Accounting checksSkipped: company is not yet profitable
- DebtUnknown
- Revenue growth, five yearsStrong, 132.2% a year
- Buying back its own sharesNo, 182% more shares since 2021
The quarter to September 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $26 million last quarter, down 64% on a year ago.
- A loss of $101 million, compared with a loss of $35 million a year ago.
- It loses 1781 cents on each $1 of sales, compared with 464 cents a year earlier.
- Over the past 12 months it spent $343 million more cash than it brought in, compared with $326 million a year earlier.
- Sales grew on a year ago in 3 of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| December 2024 | $72,000 |
| March 2025 | $72,000 |
| June 2025 | $75,000 |
| September 2025 | $71m |
| December 2025 | $132,000 |
| March 2026 | $141,000 |
| June 2026 | $284,000 |
| September 2026 | $26m |
| Quarter to | Amount |
|---|---|
| December 2024 | -$80m |
| March 2025 | -$87m |
| June 2025 | -$101m |
| September 2025 | -$35m |
| December 2025 | -$120m |
| March 2026 | -$105m |
| June 2026 | -$127m |
| September 2026 | -$101m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 26 February 2026
- Next quarterly (estimated, 10-Q)
- 3 February 2027
Who owns it
None of the long-term investors we follow own it. 214 funds in all.
Largest holders overall
- FMR$305mAdded
- BlackRock$157mAdded
- Bellevue Group AG$124m
- Paradigm Biocapital Advisors LP$124mAdded
- Kynam Capital Management, LP$119mAdded
- State Street$113mAdded
- Price T Rowe Associates$106mAdded
- Fairmount Funds Management$94mAdded
- Vanguard Capital Management$84mAdded
- Deep Track Capital, LP$66mAdded
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
8 investors own more than 5%.
- Fairmount Funds Management LLCPassive investorat least 14.0%−1.1 pts(filed with 1 related holder)Since 11 May 2026
What they said
Item 4 is hereby amended and supplemented as follows: Fund II purchased the shares of Common Stock referenced in Item 3 for investment purposes.
Read the filing - Paradigm BioCapital Advisors LPPassive investorat least 7.3%+1.2 pts(filed with 3 related holders)Since 30 September 2026
- Bellevue Group AGPassive investorat least 6.6%(filed with 1 related holder)Since 31 March 2026
- Kynam Capital Management, LPPassive investorat least 5.7%+4.2 pts(filed with 2 related holders)Since 30 June 2026
- Point72 Asset Management, L.P.Passive investorat least 5.0%(filed with 2 related holders)Since 19 August 2026
- Venrock Healthcare Capital Partners III, L.P.Passive investorat least 4.5%(filed with 6 related holders)Since 31 December 2024
- Commodore Capital LPPassive investorat least 3.9%−1.4 pts(filed with 1 related holder)Since 30 September 2025
- Deep Track Capital, LPPassive investorat least 3.3%−2.0 pts(filed with 2 related holders)Since 30 June 2026
- T. Rowe Price Associates, Inc.Passive investorSold down below 5%Since 30 September 2026
- STATE STREET CORPORATIONPassive investorSold down below 5%Since 30 September 2026
- The Vanguard GroupPassive investorSold down below 5%Since 13 March 2026
| Holder | Stake | Since | |
|---|---|---|---|
Fairmount Funds Management LLC Passive investor | at least 14.0%−1.1 pts (filed with 1 related holder) | 11 May 2026 | What they saidItem 4 is hereby amended and supplemented as follows: Fund II purchased the shares of Common Stock referenced in Item 3 for investment purposes. Read the filing |
Paradigm BioCapital Advisors LP Passive investor | at least 7.3%+1.2 pts (filed with 3 related holders) | 30 September 2026 | |
Bellevue Group AG Passive investor | at least 6.6% (filed with 1 related holder) | 31 March 2026 | |
Kynam Capital Management, LP Passive investor | at least 5.7%+4.2 pts (filed with 2 related holders) | 30 June 2026 | |
Point72 Asset Management, L.P. Passive investor | at least 5.0% (filed with 2 related holders) | 19 August 2026 | |
Venrock Healthcare Capital Partners III, L.P. Passive investor | at least 4.5% (filed with 6 related holders) | 31 December 2024 | |
Commodore Capital LP Passive investor | at least 3.9%−1.4 pts (filed with 1 related holder) | 30 September 2025 | |
Deep Track Capital, LP Passive investor | at least 3.3%−2.0 pts (filed with 2 related holders) | 30 June 2026 | |
T. Rowe Price Associates, Inc. Passive investor | Sold down below 5% | 30 September 2026 | |
STATE STREET CORPORATION Passive investor | Sold down below 5% | 30 September 2026 | |
The Vanguard Group Passive investor | Sold down below 5% | 13 March 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 1 insider bought $20m of shares on the open market. 1 sold $418,990.
- Tousignant JenniferChief Legal OfficerSold
- Date
- 19 August 2026
- Shares
- 14,212
- Price
- $24.50
- Value
- $348,194
- Fairmount Healthcare Fund II L.P.DirectorBought
- Date
- 11 May 2026
- Shares
- 1,176,470
- Price
- $17.00
- Value
- $20m
- Tousignant JenniferChief Legal OfficerSold
- Date
- 31 December 2025
- Shares
- 2,272
- Price
- $31.16
- Value
- $70,796
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 19 August 2026 | Tousignant Jennifer Chief Legal Officer | Sold | 14,212 | $24.50 | $348,194 |
| 11 May 2026 | Fairmount Healthcare Fund II L.P. Director | Bought | 1,176,470 | $17.00 | $20m |
| 31 December 2025 | Tousignant Jennifer Chief Legal Officer | Sold | 2,272 | $31.16 | $70,796 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
None of the warning signs we check for were found.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 26 Feb 2026, plus the 10-Q filed 4 Nov 2026 and 11 later 8-Ks.
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
Cheap for a reason is the question the numbers cannot answer.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.